I Live With Debilitating Psoriasis. Here’s How I Don’t Let It Defeat Me. – Men’s Health

Millions of people suffer from psoriasis, an autoimmune disease that causes painful patches of red or scaly skin called plaques to appear on the body. Flares can happen at any time, and they arent limited to spots that are easy to cover. Nor are they treatable with creams or antibiotics like other skin conditions such as eczema. Psoriasis isn't some simple rashIts a lifetime of struggle.

Those are the words of Jassem JasAhmed, a 29-year-old from London whose approach to that struggle is truly inspirational. Jass initial experience with psoriasis is a prime example of just how physically and emotionally debilitating the disease can be. He was diagnosed at 19 and soon found himself with nearly 90 percent of his body covered, and confined to his bed for nine months.

Jass was able to return to his active life, but the flares always returned. Then theyd get better, and then theyd come back, and the cycle would repeat. It still does.

But Jass wouldnt be defeated. After much trial and error and consultation with his doctors, Jass eventually found a course of treatment that suits him and his lifestyle. He also found a creative outlet to vent his anxieties: a vlog and YouTube channel where he chronicles every step of his journey. Jass doesnt sugar-coat anythinghis good days are right there next to his worse flare-ups, in all their high-definition detail. It wasnt long after posting his first video that Jass found himself with subscribers following along, asking for advice, or sending messages of thanks. Psoriasis so often carries embarrassment and shame; Jass shows people suffering from it that they arent alone. An accidental influencer perhaps, but as authentic as they come.

Wear it on your sleeve. Be proud of it, he says. I have psoriasis, it doesnt define me. Its a condition, its not who I am.

Check out the video above to learn more about living with psoriasis and how to retake control when life tries to push you off course.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Go here to read the rest:

I Live With Debilitating Psoriasis. Here's How I Don't Let It Defeat Me. - Men's Health

Explained: What is Itolizumab, newly cleared for Covid-19? – The Indian Express

Written by Anuradha Mascarenhas | Pune | Updated: July 21, 2020 7:33:30 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Also in Explained | Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

See the original post here:

Explained: What is Itolizumab, newly cleared for Covid-19? - The Indian Express

Chronic Plaque Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2017 2025 – 3rd Watch News

Insights on the Global Chronic Plaque Psoriasis Therapeutics Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Chronic Plaque Psoriasis Therapeutics market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Chronic Plaque Psoriasis Therapeutics market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/21442

Critical doubts related to the Chronic Plaque Psoriasis Therapeutics market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/21442

Segmentation of the Chronic Plaque Psoriasis Therapeutics market

The report bifurcates the Chronic Plaque Psoriasis Therapeutics market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Chronic Plaque Psoriasis Therapeutics market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Chronic Plaque Psoriasis Therapeutics market.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/21442

Important insights present in the report:

Read more:

Chronic Plaque Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2017 2025 - 3rd Watch News

Ixekizumab May Prevent Reactivation of Tuberculosis in Patients With Latent Tuberculosis Infection – Dermatology Advisor

Ixekizumab, and other antibodies that target interleukin 17 monoclonal antibody (IL-17A), may reduce reactivations of tuberculosis in patients with latent tuberculosis infection (LTBI), according to a study research published in the Journal of the American Academy of Dermatology.

The findings were from a post hoc analysis of integrated safety data from 13 clinical trials of patients with psoriasis (n=5898) and 3 trials of patients with psoriatic arthritis (n=1118). The safety analyses reported treatment-emergent LTBI in patients who were treated with ixekizumab. Assessment of LTBI was made with the purified protein derivative skin test or QuantiFERON-TB Gold assay. Only patients who tested negative for LTBI either at screening or <3 months before baseline were included in the post hoc analysis.

It was noted that 1.7% (n=101) of patients with psoriasis developed treatment-emergent LTBI, and 65 of these patients discontinued ixekizumab. A total of 30 patients who remained in their trial initiated LTBI-specific therapy, whereas the other 6 patients who continued in their trial did not receive therapy.

It was found that 2.9% (n=32) of patients with psoriatic arthritis developed treatment-emergent LTBI, and 7 of the 12 patients who continued ixekizumab also received LTBI therapy. Only 5 patients were not treated with a LTBI-specific therapy. None of the 6 patients with treatment-emergent LTBI without LTBI-specific therapy during ixekizumab experienced reactivation of their disease.

Limitations of the analysis were the lack of a control group, the small number of events, and the short observation time.

The investigators wrote that additional real-world data are needed to address the clinical question on the potential long-term risk for reactivation of tuberculosis under anti-IL 17 therapy.

Disclosure: This clinical trial was supported by Eli Lilly and Company. Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis [published online June 8, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.06.012

Read more:

Ixekizumab May Prevent Reactivation of Tuberculosis in Patients With Latent Tuberculosis Infection - Dermatology Advisor

Psoriasis Drugs Market: Information, Figures and Analytical Insights 2019-2026 – Cole of Duty

Most recent report on the global Psoriasis Drugs market

A recent market study reveals that the global Psoriasis Drugs market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Psoriasis Drugs market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Psoriasis Drugs field.

Valuable Data included in the report:

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

Some of the top tier players profiled in the report include:

Product adoption Analysis

A complete assessment of the market share, consumption patterns, and supply-demand ratio of each product is provided backed by insightful tables, figures, and graphs. The products covered in the report include:

The resourceful market study outlines the overall prospects of the Psoriasis Drugs market in the major geographies including region 1, region 2, region 3, and region 4. The most prominent market players, observable trends, opportunities, and challenges in each region is enclosed in the report.

Important Queries Addressed in the report:

Why Our Clients Trust Psoriasis Drugs Market Report?

With a systematic and methodic approach, our analysts collect data from credible primary and secondary sources. In addition, we offer the most efficient after sales services to our customers and address their problems without any delay.

See original here:

Psoriasis Drugs Market: Information, Figures and Analytical Insights 2019-2026 - Cole of Duty

What Are Your Psoriatic Arthritis Treatment Options? – HealthCentral.com

On this page:Basics

Even though theres no cure for psoriatic arthritis (PsA), relief for your symptoms is likely just around the metaphorical cornerthe research into treating this inflammatory condition is moving that fast. Drug therapies for PsA are more targeted than ever, and lifestyle changes can make big improvements in your condition. Once youve been diagnosed with PsA, your primary care doctor will likely refer you to a rheumatologist to discuss your treatment options. Lets take a closer look at what those might entail.

Driven by an out-of-whack inflammatory response, psoriatic arthritis (PsA) is a chronic condition where your joints, ligaments, and tendons come under attack by your immune system, leading to pain, swelling, and stiffness that can do serious joint damage if left unchecked.

The disease is related to (but different from) the inflammatory skin condition known as psoriasisalthough about 30% of people with psoriasis will develop PsA at some point during their life, most commonly in their 30s and 40s.

While the jury is still out on the exact causes of PsA, experts believe it is a combination of genetics (about 40% of people with PsA have a family history of the disease), an overactive immune system, and things in the environment that you have been exposed to. It affects men and women in equal numbers and is most frequently diagnosed in people between the ages of 30 and 50.

When it comes to PsA treatment, one size doesnt fit all. Before deciding which approach is right for you, your doctor will do a physical exam and ask you questions to figure out how much (or little) PsA is getting in the way of your everyday activities.

Severe cases can cause long-term joint damage, while milder cases are more of an inconvenience, so its important to establish the degree to which PsA is affecting your personal situation first, before talking about treatment.

The goal of the treatment is simple: Reduce inflammation and the discomfort that you may be feeling so you can return to enjoying your life. The sooner treatment begins, the more successful it tends to be at easing symptoms and slowing down the disease. These are a few of the approaches you and your doc may discuss.

Uncontrolled inflammation is the underlying cause of most of the discomfort associated with psoriatic arthritis. How severe your inflammation is will often determine which treatment your doctor will chooseor at least, which therapy you start with. Fortunately, there are many effective medications available. You may find that you need to try several in combination to get the best results.

NSAIDs are usually the first step if your symptoms are very mild. They can help control the inflammation and joint pain. Some people feel relief almost immediately, while in others it may take several days. These drugs are not recommended for long-term use since they carry side effects like stomach irritation, heart problems, and kidney damage.

The most common NSAIDs include:

In addition, COX-2 inhibitors, a subclass of NSAIDs, may be prescribed. These have a lower risk of internal bleeding or stomach ulcersa common side effect of other NSAIDs that are used in large doses for a long time. Brand names include Bextra and Celebrex (celecoxib).

Shorthand for disease-modifying anti-rheumatic drugs, these treatments used to be the go-to regimen for treating PsA. They work by suppressing the bodys overactive immune system. Due to their immune-suppressing nature, they can come with side effects, like mouth sores, hair loss, stomach upset, infection, fatigue, or liver damage. If you are taking them, you should be closely monitored with regular (weekly to every few months) lab tests. Most DMARDs can all be taken orally, and methotrexate is also available as an injection.

The most common DMARDs include:

A sub-type of DMARDS, known as JAK inhibitors (short for Janus kinase) target a family of enzymes that trigger the immune system response. Drugs include:

Also known as biologic response modifiers, these medications hold much promise for the future of PsA treatments: Up to 60% of PsA patients achieved minimal disease activity after one year of treatment with biologics, according to a study in Arthritis Research & Therapy. These therapies have fewer side effects than DMARDs (although your risk of infection is greater).

Heres how they work: Biologics are protein-based drugs derived from living cells cultured in a laboratory. Their job is to control certain parts of the immune system by targeting the proteins that fuel inflammation and shutting them down. They are categorized based on the cells they target.

These are a few options your doctor may prescribe:

This class of drugs is now the first line of prescription treatment for people with PsA, according to guidelines issued in 2018 by the National Psoriasis Society and the American College of Rheumatology. These meds lower inflammation and slow the progression of PsA by targeting an inflammation-causing substance in the body called tumor necrosis factor (TNF).

Delivered by self-injection or IV, examples of TNF inhibitors include:

Another type of biologic treatment that has been found to be effective in treating PsA, these drugs act on a different pathway to control inflammation in your joints. Like TNF inhibitors, these meds are only available via infusion or injection.

Examples include:

A type of white blood cell related to your immune system, T-cells signal to your body that its under attack and time to launch an assault. Unfortunately, that assault, by way of inflammation, is mistakenly directed at your joints and tendons.

This class of medication inhibits T-cells from becoming activated, thereby reducing inflammation and subsequent joint damage. Its taken as an injection. Examples include Orencia (abatacept).

These drugs work by blocking an enzyme called phosphodiesterase 4 (PDE4), that is responsible for controlling inflammatory actions within the bodys cells. Currently there is only one PDE4 inhibitor approved for PsA. This drugOtezla (apremilast)can be taken orally.

Consider corticosteroids a short-term fix for symptoms while youre waiting for other longer-term medications to take effect. (They can also be prescribed for immediate relief during a flare.) Corticosteroids can be taken orally, intravenously, or injected right into the joint.

Long-term use should be avoided since it can lead to side effects like high blood sugar, high blood pressure, bone loss, and glaucoma. Patients coming off the drug should taper slowly over a few weeks. The most common corticosteroid is Deltasone (prednisone).

Surgery is not a standard treatment for those with PsA. However, if youve lived with psoriatic disease without a diagnosis or treatment, it is possible that it has caused permanent joint damage, in which case, your doctor may talk with you about arthoplastya procedure that replaces, reshapes, or reconstructs damaged joints.

Its a serious surgery, but also a common one: More than a million joint replacement procedures are performed each year, mostly of the hip or knee (your shoulders, elbows, and joints in the hands and feet can be replaced as well). There are pros and cons to going this routeand its usually reserved for the most severe cases of joint damage. Talk with your doctor if its something you think might help.

Along with medical procedures and drug intervention, there are a bunch of lifestyle changes you can make that will go a long way towards easing the painful symptoms of psoriatic arthritis. This list here can help you get started.

Drink less alcohol. Heavy drinking can lower your response to PsA treatment. Unchecked alcohol consumption will also fill you up with a glut of empty calories, leading to unwanted pounds that place extra stress on your joints.

Exercise more. Exercising regularly can help psoriatic arthritis in several ways: It reduces joint pain by keeping muscles strong and supporting the joints; it helps you lose or maintain a healthy weight so there is less load on your joints and ligaments; and it can improve your mood and reduce stress. If you are having a flare, you will need to listen to your body. Dont be afraid to back off or take more frequent breaks as you work out. After all, any amount of exercise is better than none.

Explore hot/cold therapy. A warm shower or bath can work wonders on stiff, painful joints. Heat reduces muscle tension and stimulates blood circulation, which may help joints feel better. (Heat can also irritate your skin and cause a flare, so its a tricky balance.) A cold compress, on the other hand, may help reduce inflammation, swelling, and soreness during a flare or after more than your usual amount of activity.

Manage stress. The bottom line: Stress can trigger a flare. Try exercise, meditation, yoga, or deep breathing if tension is making your symptoms worse. And if anxiety or depression is interfering with your life or ability to function, dont hesitate to seek help.

Quit smoking. Smoking can increase your risk of psoriasis and may make symptoms significantly worse. It can also prevent your treatment for working effectively. While the exact causes are unknown, one theory is that cigarettes contain thousands of different ingredients that may promote inflammation.

Sleep better. Sleep is incredibly important for everyone, but if you have psoriatic arthritis, it's especially key because a major part of joint and tissue repair happens when you are asleep. Unfortunately, pain related to PsA can interrupt sleep and so can certain medications like steroids. If youre struggling to get a steady seven to nine hours a night, talk with your doctor about possible solutions.

Use topical creams. Applying creams or lotions containing capsaicin (an extract from chili peppers) may temporarily soothe minor joint pain. Ditto for those with camphor, menthol, or turpentine oil.

Watch your diet. While a direct correlation between diet and psoriatic arthritis has yet to be proven, avoiding foods known to trigger inflammation in the body is sort of a no-brainer. Desserts, soda, white bread, and other foods that are high on the glycemic index tend to cause a temporary spike in blood sugar, which promotes inflammation.

Wear supportive shoes. Sorry to say it, but your days of flip flops and cheap shoes may be behind you. Shoes that provide stability and cushioning can help your feet feel better and provide a solid foundation for your knees, hips, back, and neck. Do what you need to stay comfortable and supported. You may find that changing shoes several times a day is preferable.

There isnt a ton of research to say conclusively one way or the other, but theres little downside to adding these two natural supplements into your diet.

A few studies suggest that supplementation of about 3.3 grams daily of fish oil, which contains high amounts of omega-3 fatty acids, may help reduce pain and stiffness. Salmon, walnuts, and flax seed are also sources of omega-3s. Dont overdo though: High doses of omega-3 supplements can cause nausea, cramps, and increase bleeding risks in people who take blood thinners. As always, talk with your doc first.

Turmeric has been used as a spice for centuries. Several small studies show that turmeric and its major ingredient (curcumin) may help treat arthritis symptoms just as effectively as pain medicines like ibuprofen. You can find it as a supplement and can also use it to cook with or add to your tea or smoothies.

All of these options may sound overwhelming to you. Its hard to know where to startwhich is why the best thing you can do is make a list of questions and schedule an appointment with your doctor. As you talk, keep your mind focused on the fact that with the right treatment, the majority of those living with PsA get their symptoms under control and achieve remission. In fact, with certain treatment programs, more than half of patients see symptoms virtually disappear in a years time. Pretty good!

Of course, the trick is finding the right combination of meds, and that can be a bit of trial and error. Dont give up. It can take months, but once you settle of a combo that works for you, youll be well on your way to getting your life back the way you want it. Most likely, youll need to stay on the meds indefinitely, since even though the disease may quiet down, its there, waiting to strike if given half a chance. Still, thats a small price to pay for pain-free living.

Thats a doctor who is specially trained in diagnosing and treating PsA and other rheumatic diseases (musculoskeletal diseases and systemic autoimmune disorders). To see one, you may need a referral, either from your primary care doc or another physician.

Nope, sorry. PsA is not yet curable. If you are taking medication and your symptoms improve, do not stop taking your medications without talking to your doctor. Discontinuing your medications could cause your symptoms to return and even get worse.

PsA treatment varies as does the time it takes to see results. For example, you may get immediate relief from a cortisone injection, but it may take months for a biologic medication to work effectively.

Actually, yes. Kids can get this disease, and when they do, its referred to as pediatric psoriatic arthritis. If your child shows symptoms, seek treatment as soon as possible. The approach will be similar for that of adults with PsA.

Read the original here:

What Are Your Psoriatic Arthritis Treatment Options? - HealthCentral.com

This Pro Wrestler Overcame His Skin Condition and Got His Swagger Back – Men’s Health

There are an estimated 8 million people in the United States living with psoriasis, a chronic condition that results in painful skin lesionsraised, scaly patches called plaques, boils (known as pustules), or areas of redness and swelling. For affected folks, the threat of a flare-up is always lurking, constantly shaking their confidence in social situations, at school, or at work. That's tough enough to deal with when you can hide within the walls of your cubicle. But what do you do when your "office" is the squared circle?

Growing up in Rochester, New York, Dewey Murray had a singular career goal: wrestle in the WWE. A psoriasis diagnosis at the age of 13 did nothing to derail that dream. At 15, he graduated from a local wrestling academy. By 18, he was building his name on the indie wrestling circuit.

Though the storylines and match results were choreographed, the stunts still carried massive risks. For Murray, the opportunity to conquer the fear of those high-flying physical feats was one of the best features of his job. He could get past putting himself at great risk of injury (or worse). Hell, he embraced it. But when it came to the fear of an in-ring skin flare-up that would bring judgementfrom his fellow wrestlers, the thousands in attendance, and millions watching at homethat anxiety was almost too much.

This is not your average day job. Youre in physical contact with your coworkers.

At just 23 years old and having booked his first gig with the WWE, what should have been a dream come true was rapidly devolving into a nightmare scenario. Murray's big-league debut would require him to have his head shaved in an arena filled with 14,000 screaming wrestling fans, for a segment broadcast live on TV. This should have been his career-launching moment, but all Murray could think about was how his psoriasis might blow the whole thing.

How bad were his plaques? Would the camera be close enough to show them? What would his head look like shaved? What if he bled? What about the guys wielding the electric razor? They were wrestlers, not professional barbers. As the unanswerable questions mounted and Murray imagined the many ways things could go wrong, he was filled with dread.

So much goes through your head because its on live TV and theres no redo, no Hey I have this spot showing, lets hit makeup and run back out and redo it, says Murray, now 32. Im not one to be honest about my anxiety, but that was by far the most stressful day with having psoriasis.

Today, Murray looks back on that day as one of his happiest in wrestling. The spot went well, the few patches he had on his scalp weren't visible on TV, and afterward when he visited a stylist, she didn't mention anything while cutting his hair.

Still, Murray's psoriasis affected his confidence on the job. Other wrestlers knew about Murray's condition; some refused to get in the ring with him, even though it isnt contagious. Mostly, he worried about the crowd finding out. Its one thing when you can go to work every day and dress in a way that hides your skin condition, but as a wrestler you arent able to do that, he says.

About a year after the head-shaving stunt, to control what the crowd saw, Murray developed a trucker persona that allowed him to dress in layers from head to toe, so fans would be none the wiser. He wore jeans with a big flannel shirt and wrapped bandanas around his elbows to hide flare-ups. When the bandanas proved popular with fans, Murray sold them at merch tables. Theres always a positive with the negative, he likes to say.

Murray's trucker persona did the trick. Since 2011, he's had steady work for the likes of Ring of Honor, Total Nonstop Action, and more appearances with WWE; in 2015, he even cracked the world top-500 rankings in Pro Wrestling Illustrated. But while his career continued, keeping his skin condition under wraps took a psychological toll.

At one particular match, Murrays opponentsomeone he had idolized over the yearswas late to arrive, so they didnt have a chance to meet beforehand. After the match was over, Murray sought him out to formally introduce himself. As he extended his hand, the wrestler told him, Im not going to shake your herpes hand.

This is not your average day jobHey Susan, hows it going?this is wrestling. Youre in physical contact with your coworkers, Murray says. When that happened, I didnt know whether to hit him or cry.

This content is imported from Twitter. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Finally, in 2017, after trying virtually every possible treatmentphoto light-boxes that left burn marks, coal tar shampoo and body wash, sea salt soaks, a hundred creams, lotions, oils, pills, and injectablesMurray, with the help of his dermatologist, found a biologic that worked for him. He hasnt had a flare-up since.

Today, Murray is still in the ring, touring the US and Canada on the indie wrestling circuit as an independent contractor, and occasionally appearing on TV, free of anxiety. Before, I was scared to do certain stuff [in the ring] because I was afraid of hitting the wrong way and bleeding everywhere because of the plaques on my body, he says. [Now,] its amazing to go out there and do crazy stuff and know that if a bandana comes off, I dont have to tie it back on. Professionally, I dont have a care in the world.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

More here:

This Pro Wrestler Overcame His Skin Condition and Got His Swagger Back - Men's Health

Food Triggers for Psoriasis: What to Eat and What to Avoid

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

When you have psoriasis, reducing triggers is an important part of managing your condition and avoiding flare-ups. Psoriasis flare-ups can be caused by a variety of triggers. These triggers may include bad weather, excess stress, and certain foods.

Lets take a look at the foods that are most likely to trigger a psoriasis flare-up. There are some foods that are helpful to incorporate and certain diets to consider when creating a treatment plan for your psoriasis.

The foods listed below have been reported to trigger flare-ups, but they may not affect all those affected by psoriasis.

With psoriasis, its important to avoid foods that can trigger inflammation. Inflammation and the immune system response can lead to a flare-up.

Both red meat and dairy, especially eggs, contain a polyunsaturated fatty acid called arachidonic acid. Past research has shown that by-products of arachidonic acid may play a role in creating psoriatic lesions.

Foods to avoid include:

Celiac disease is a health condition characterized by an autoimmune response to the protein gluten. People with psoriasis have been found to have increased markers for gluten sensitivity. If you have psoriasis and a gluten sensitivity, its important to cut out gluten-containing foods.

Foods to avoid include:

Eating too many processed, high-calorie foods can lead to obesity, metabolic syndrome, and a variety of chronic health conditions. Certain conditions such as these cause chronic inflammation in the body, which may be linked to psoriasis flare-ups.

Foods to avoid include:

One of the most commonly reported triggers for psoriasis flare-ups is the consumption of nightshades. Nightshade plants contain solanine, which has been known to affect digestion in humans and may be a cause of inflammation.

Foods to avoid include:

Autoimmune flare-ups are linked to the health of the immune system. Alcohol is believed to be a psoriasis trigger due to its disruptive effects on the various pathways of the immune system. If you have psoriasis, it may be best to drink alcohol very sparingly.

With psoriasis, a diet high in anti-inflammatory foods can help to reduce the severity of a flare-up.

Almost all anti-inflammatory diets include fruits and vegetables. Fruits and vegetables are high in antioxidants, which are compounds that decrease oxidative stress and inflammation. A diet high in fruits and vegetables is recommended for inflammatory conditions such as psoriasis.

Foods to eat include:

A diet high in fatty fish can provide the body with anti-inflammatory omega-3s. The intake of omega-3s has been linked to a decrease of inflammatory substances and overall inflammation.

Fish to eat include:

It should be noted that there is still more research that needs to be done on the link between omega-3s and psoriasis.

Like fatty fish, certain vegetable oils also contain anti-inflammatory fatty acids. Its important to focus on oils that have a higher ratio of omega-3 to omega-6 fatty acids.

Oils to eat include:

A 2013 review of research literature showed that nutritional supplements may help reduce inflammation in psoriasis. Fish oil, vitamin D, vitamin B-12, and selenium have all been researched for psoriasis.

Benefits of supplementation with these nutrients may include a decrease in the frequency and severity of flare-ups.

Not all diets are good for psoriasis. Here are some options you may want to consider when choosing the best diet for your condition.

Dr. Pagano was well known within the health and wellness community for his approach to healing psoriasis through diet. In his book, Healing Psoriasis: The Natural Alternative, he describes how a healthy diet and lifestyle can improve psoriasis naturally.

Dr. Paganos dietary approach includes:

A 2017 survey of more than 1,200 people with psoriasis indicated that the Pagano diet is one of the most successful diets for improving psoriasis outcomes.

In people who have both psoriasis and gluten sensitivities, a gluten-free diet may provide some improvement. One small 2018 study found that even people with mild gluten sensitivities can benefit from following a gluten-free diet.

Of the 13 participants who were placed on a gluten-free diet, all observed an improvement in their psoriatic lesions. The biggest benefit was observed for those participants with the strongest sensitivity.

A vegan diet may also benefit people with psoriasis. This diet is naturally low in inflammatory foods such as red meat and dairy. Its high in anti-inflammatory foods such as fruits, vegetables, and healthy oils.

Like the Dr. Pagano diet, the vegan diet also showed favorable results in study participants with psoriasis.

Speak with your doctor about following a vegan diet, as you need to be careful to get all the nutrients you need.

The Mediterranean Diet is well known for its numerous health benefits, including a reduced risk of certain chronic diseases. This diet focuses on foods that are high in antioxidants and healthy fats. It limits foods that are often considered to be pro-inflammatory.

In a 2015 study, researchers found that people with psoriasis are less likely to be consuming a Mediterranean-type diet than their healthy counterparts. They also found that those who did adhere to elements of the Mediterranean diet had a lower disease severity.

The paleo diet places an emphasis on eating whole foods and avoiding processed foods. Since many whole foods contain anti-inflammatory compounds, this diet may prove to be beneficial for people with psoriasis.

Unlike Dr. Paganos diet, it involves eating plenty of meat and fish. However, the 2017 research suggests that the paleo diet is the third most effective diet in people with psoriasis.

The autoimmune protocol diet (AIP) focuses on eliminating foods that might cause inflammation. This diet is incredibly restrictive and primarily includes vegetables and meat, with certain oils and herbs mixed in.

It might not be appropriate for people with psoriasis, as too much meat is considered a trigger for flare-ups. In addition, its not intended to be a long-term dietary intervention.

This popular low-carb diet has many touted health benefits, such as weight loss and improved nutrient markers. Its true that reducing carbohydrates can help reduce processed food intake.

However, reducing carbohydrates also means reducing many anti-inflammatory fruits and vegetables. It also necessitates increasing protein from meat. Because certain keto foods can be triggers in people with psoriasis, this diet may not be recommended.

Many autoimmune conditions such as psoriasis can benefit from dietary changes. If you have psoriasis, you may find it beneficial to include plenty of anti-inflammatory foods, such as fruits, vegetables, and healthy oils.

You may also want to avoid pro-inflammatory foods, such as meat, dairy, and processed foods. These dietary changes may help to reduce the frequency and severity of your flare-ups.

Its always best to reach out to a physician or nutritionist for more information on how your diet can help control your condition.

See the original post here:

Food Triggers for Psoriasis: What to Eat and What to Avoid

Psoriatic Arthritis: Causes, Symptoms, and Treatments – Self

Overview

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasisa condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin lesions appear.

Joint pain, stiffness, and swelling are the main symptoms of psoriatic arthritis. They can affect any part of your body, including your fingertips and spine, and can range from relatively mild to severe. In both psoriasis and psoriatic arthritis, disease flares may alternate with periods of remission.

No cure for psoriatic arthritis exists, so the focus is on controlling symptoms and preventing damage to your joints. Without treatment, psoriatic arthritis may be disabling.

Symptoms

Both psoriatic arthritis and psoriasis are chronic diseases that get worse over time, but you may have periods when your symptoms improve or go into remission alternating with times when symptoms become worse.

Psoriatic arthritis can affect joints on just one side or on both sides of your body. The signs and symptoms of psoriatic arthritis often resemble those of rheumatoid arthritis. Both diseases cause joints to become painful, swollen, and warm to the touch.

However, psoriatic arthritis is more likely to also cause:

When to see a doctor

If you have psoriasis, be sure to tell your doctor if you develop joint pain. Psoriatic arthritis can severely damage your joints if left untreated.

Causes

Psoriatic arthritis occurs when your bodys immune system begins to attack healthy cells and tissue. The abnormal immune response causes inflammation in your joints as well as overproduction of skin cells.

Its not entirely clear why the immune system turns on healthy tissue, but it seems likely that both genetic and environmental factors play a role. Many people with psoriatic arthritis have a family history of either psoriasis or psoriatic arthritis. Researchers have discovered certain genetic markers that appear to be associated with psoriatic arthritis.

Physical trauma or something in the environmentsuch as a viral or bacterial infectionmay trigger psoriatic arthritis in people with an inherited tendency.

Risk factors

Several factors can increase your risk of psoriatic arthritis, including:

Complications

A small percentage of people with psoriatic arthritis develop arthritis mutilansa severe, painful, and disabling form of the disease. Over time, arthritis mutilans destroys the small bones in your hands, especially the fingers, leading to permanent deformity and disability.

Here is the original post:

Psoriatic Arthritis: Causes, Symptoms, and Treatments - Self

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 Bulletin Line – Bulletin Line

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

Excerpt from:

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 Bulletin Line - Bulletin Line

Explained: What is Itolizumab, newly cleared for Covid? – The Indian Express

Written by Anuradha Mascarenhas | Pune | Updated: July 20, 2020 8:09:55 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

What is this drug?

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Explained |Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

Link:

Explained: What is Itolizumab, newly cleared for Covid? - The Indian Express

Psoriasis Drugs Market: Competitive Intelligence and Tracking Report 2018 2028 – 3rd Watch News

Growth Prospects of the Psoriasis Drugs Market

The comprehensive study on the Psoriasis Drugs Market provides crucial insights to the stakeholders who are vying to solidify their presence in the current and future market landscape. The various factors that are likely to shape the course of the Psoriasis Drugs Market over the next decade are thoroughly analyzed in the report.

The research report provides deep insights into the competitive outlook of the Psoriasis Drugs Market. The research report looks into growth strategies employed by key players, and how these strategies are poised to change the competitive dynamics in the Psoriasis Drugs Market over the forecast period. Further, our research reports include market share estimates and changing hierarchy in the Psoriasis Drugs Market over the forecast period. The influence of growth strategies on the changing hierarchy in the Psoriasis Drugs Market is also discussed in this report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/3119

Important doubts pertaining to the Psoriasis Drugs Market addressed in the report:

The extensive report fragments the Psoriasis Drugs market into multiple segments such as product type, regions, end uses, and industries.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Psoriasis Drugs Market.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/3119

Competition Outlook

The market study provides valuable insights related to the major players involved in the Psoriasis Drugs Market. The study includes information related to the recent mergers, acquisitions, collaborations, product launches, and research & development activities.

The report covers exhaustive analysis on:

Regional analysis includes:

Get Full Report Access athttps://www.xploremr.com/cart/3119/SL

Analytical insights included in the report:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id- [emailprotected]

Continue reading here:

Psoriasis Drugs Market: Competitive Intelligence and Tracking Report 2018 2028 - 3rd Watch News

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 – Bulletin Line

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

Originally posted here:

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 - Bulletin Line

Systemic Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 – Cole of Duty

Insights on the Global Systemic Psoriasis Therapeutics Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Systemic Psoriasis Therapeutics market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Systemic Psoriasis Therapeutics market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3086

Critical doubts related to the Systemic Psoriasis Therapeutics market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3086

Segmentation of the Systemic Psoriasis Therapeutics market

The report bifurcates the Systemic Psoriasis Therapeutics market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Systemic Psoriasis Therapeutics market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Systemic Psoriasis Therapeutics market.

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3086

Important insights present in the report:

Read the original post:

Systemic Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 - Cole of Duty

Global Plaque Psoriasis Treatment Market to Witness Rapid Development During the Period 2017 2025 – Jewish Life News

Plaque psoriasis is a chronic, autoimmune inflammatory disorder which leads to overproduction of skin cells. The skin is characterized by inflamed, raised, scaly, red plaques and lesion. The intensity and frequency of psoriasis are affected by environmental factors such as sun exposure, smoking, HIV infection, and alcoholism. Metabolic syndrome and cardiovascular disease are common in psoriasis patients. Psoriasis increases the chances of myocardial infarction in younger psoriasis patients by three folds.

Moreover, severe psoriasis leads to 3.5 years reduced life expectancy in males relative to individuals without psoriasis. Psoriasis arthritis is a distinct syndrome which occurs in one-third of psoriasis patient with the onset of rheumatic arthritis.

Psoriasis plaque are distinguished by three features, an infiltrate featuring T-cells, the extravagant growth of poorly differentiated keratinocytes and the presence of dilated dermal blood vessels. Most of the introduced therapies for psoriatic were developed as to target T-cells or their inflammatory mediators including cytokines, receptors, and ligands.

Plaque Psoriasis Treatment Market: Dynamics

The demand for plaque psoriasis treatment market is expected to boom with the increasing number of pipeline psoriasis molecule and the number of biologics being launched. Janssen Biotec is seeking for the market approval of Guselkumab. The molecule is in the Phase III trial as a subcutaneous administered therapy for the treatment of plaque psoriasis.

Moreover, Gelantin Therapeutics Inc. announced positive data from its phase 2 study of its drug GR-MD-02 to treat moderate-to-severe plaque psoriasis. The company is now seeking for strategic partnership for its drug development program.

The advent of biologics has also shifted the preference from systemic therapy to meet the existing need. The systemic therapy suppresses the entire immune system as the clinician needs to do routine laboratory monitoring because of myelosuppression, hematologic side effects and increased renal and liver toxicity. Moreover, the systemic therapy is also contraindicated in nursing mothers, pregnant women, and individuals with kidney and liver diseases.

Around 125 million people worldwide have psoriasis out of which 80%, have plaque psoriasis. The need for safe plaque psoriasis therapy in children is essential as about one-third of the psoriasis cases are in children. Etanercept was approved by the DA as an extended indicated for children of age 4 and above.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/16069

Plaque Psoriasis TreatmentMarket: Segmentation

On the basis therapy the plaque psoriasis treatment market can be segment as:

Phototherapy and systemic therapy should only be used in cases where a topical treatment is inadequate. Novel systemic treatments are now being introduced where a range of biologics are sed. The mode of treatment follows a psoriasis treatment ladder. Initially, topical treatment is given, if the skin fails to respond then phototherapy is given. The third step involves the use of systemic treatment which may be through the administration of pills or injection.

On the basis drug class the plaque psoriasis treatment market can be segment as:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/16069

TNF- inhibitor was the first class of biologics which were successful in delivering the treatment while still maintaining the safety profile. Enbrel was the first molecule to be approved followed by Remicade and Humira. The introduction of these molecules increased the overall sales of the psoriasis drugs and also increased the physicians comfort and familiarity.

Plaque Psoriasis TreatmentMarket: Region-wise Outlook

North America region dominates the plaque psoriasis market owing to the increasing approval of pipeline drugs and supplemental biologics. In November 2016, the FDA approved supplemental biologics license for the use of Etanercept for children aged four and older having moderate-to-severe plaque psoriasis. The approval is the first of its kind indicated for the treatment of adults with moderate-to-severe plaque psoriasis. Amgen had performed a year-long phase 3 study and 5-year open-label extension testing for the approval.

AsiaPacific is expected to be the fastest-growing region owing to the huge population base and changing lifestyle habits such as smoking. Moreover, the global market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/16069

Plaque Psoriasis TreatmentMarket: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Read more:

Global Plaque Psoriasis Treatment Market to Witness Rapid Development During the Period 2017 2025 - Jewish Life News

India clears a psoriasis drug for COVID-19, and a tiny US biotech’s shares soar – BioPharma Dive

Dive Brief:

The battle against the new coronavirus is being waged on multiple fronts, from vaccines to prevent infection to other drugs meant to treat and manage COVID-19's many complications.

One of those complications is an overactive immune response, seemingly similar to cytokine release syndrome or CRS, which can cause potentially deadly damage to the lungs or other organs.

Researchers and scientists have been testing other anti-inflammatory drugs against that damaging immune response,but thus far have yet to succeed. The Sanofi and Regeneron arthritis drug Kevzara has failed to deliver a clear benefit in clinical trials, while a similar drug from Roche came up short in a small Italian study after flashing promise earlier.

A larger, more rigorous Actemra trial is still underway, as are tests of the cancer therapies Jakafi and Calquence.

The only drug that has conclusively been shown to reduce death in a large trial of hospitalized COVID-19 patients is the steroid dexamethasone.

But that study, called RECOVERY, didn't look at whether patients where suffering from immune responses characteristic of CRS.Indeed, the mass repurposing of drugs to target COVID-19 related CRS has alarmed some experts, fearful of causing more harm than good.

A JAMAeditorial published in late June highlighted that what is being defined as "cytokine storm" isn't fully understood, and treating those patients with drugs that indiscriminately suppress the immune system "raises concerns about impaired clearance of SARS-CoV-2 and increased risk for secondary infections."

Yet Indian drugmaker Biocon, the developer of plaque psoriasis drug called itolizumab, has claimed success in a study of 30 patients hospitalized with COVID-19 who have CRS and moderate to severe acute respiratory distress syndrome. Bioconreported that in a controlled trial, all 20 people who got itolizumab and standard treatment recovered. Three of the 10 on standard treatment alone died. Decreases in various key markers of inflammation as well as measures of oxygen levels were seen in itolizumab patients as well, according to the company.

Biocon has not provided specifics yet, however, making its claims impossible to fully assess. Still, the results were encouraging enough for the Indian government to clear use of itolizumab in very sick COVID-19 patients. That, along with additional data being generated in Cuba, where the drug was discovered, "could pave the way for discussions with regulators and other government agencies to pursue clinical development and funding in the U.S.," wrote SVB Leerink analyst Thomas Smith.

Results from an open-label, uncontrolled 24-patient study in Cuba currently under a peer review at the journal Immunity & Ageing found that itolizumab appeared to significantly reduce levels of the inflammatory protein IL-6 in the blood. The Cuban government in May also credited the use of itolizumab for an apparent reduction in deaths from COVID-19 among its citizens, though those results didn't come from a randomized, controlled trial.

Unlike Actemra and Kevzara, which inhibit an inflammatory protein called IL-6, Itolizumab blocks CD6, a protein found on the surface of many immune cells, among them effector T cells that drive inflammation in a variety of diseases. The drug was approved in India in 2013 to treat chronic plaque psoriasis under the brand name Alzumab. Equillium has since licensed rights in the U.S., Canada, New Zealand and Australia and has been aiming to develop it for a number of inflammatory conditions like asthma and lupus.

In light of the news from India, Equillium said it plans to ask the Food and Drug Administration to start a global randomized trial of itolizumab. Equillium shares more than doubled, to over $8 apiece, though that's still less than the $14 per share price at which the company went public in 2018.

Equillium had to stall testing of itolizumab which it calls EQ001 due to the pandemic. But it said Monday that those trials have now resumed.

Excerpt from:

India clears a psoriasis drug for COVID-19, and a tiny US biotech's shares soar - BioPharma Dive

Sorting Out the Many Mimickers of Psoriasis – Medscape

Of the many psoriasis mimicker clinicians are likely to encounter, atopic dermatitis is likely the most common one, especially the nummular eczema variant form.

"It has an earlier age of onset, usually in infancy, and can occur with the atopic triad that presents with asthma and seasonal allergies as well,"Israel David "Izzy" Andrews, MD, said at the virtual Pediatric Dermatology 2020: Best Practices and Innovations Conference. "There is typically a very strong family history, as this is an autosomal dominant condition, and it's far more common than psoriasis. The annual incidence is estimated to be 10%-15% of pediatric patients. It has classic areas of involvement depending on the age of the patient, and lesions are intensely pruritic at all times. There is induration and crust, but it's important to distinguish crust from scale. Whereas crust is dried exudate, and scale is usually secondary to a hyperproliferation of the skin. Initially, treatments (especially topical) are similar and may also delay the formalized diagnosis of either of the two."

Another psoriasis mimicker, pityriasis rosea, is thought to be secondary to human herpesvirus 6 or 7 infection, said Dr. Andrews, of the department of dermatology at Phoenix Children's Hospital. It typically appears in the teens and tweens and usually presents as a large herald patch or plaque on the trunk. As the herald patch resolves, smaller lesions will develop on the trunk following skin folds. "It's rarely symptomatic and it's very short-lived, and clears within 6-12 weeks," Dr. Andrews noted. "It can present with an inverse pattern involving the face, neck, and groin, but sparing the trunk. This variant, termed inverse pityriasis rosea, can be confused with inverse psoriasis, which has a similar distribution. However, the inverse pattern of pityriasis rosea will still resolve in a similar time frame to its more classic variant."

Pityriasis lichenoides can also be mistaken for psoriasis. The acute form can present with erythematous, scaly papules and plaques, but lesions are often found in different phases of resolution or healing. "This benign lymphoproliferative skin disorder can be very difficult to distinguish from psoriasis and may require a biopsy to rule in or out," Dr. Andrews said. "It can last months to years and there are few treatments that are effective. It is typically nonresponsive to topical steroids and other treatments that would be more effective for psoriasis, helping to distinguish the two. It is thought to exist in the spectrum with other lymphoproliferative diseases including cutaneous T-cell lymphoma [CTCL]. However, there are only a few cases in the literature that support a transformation from pityriasis lichenoides to CTCL."

Seborrheic dermatitis is more common than atopic dermatitis and psoriasis, but it can be mistaken for psoriasis. It is caused by an inflammatory response secondary to overgrowth of Malassezia yeast and has a bimodal age distribution. "Seborrheic dermatitis affects babies, teens, and tweens, and can persist into adulthood," he said. "Infants with cradle cap usually resolve with moisturization, gentle brushing, and occasional antifungal shampoos." Petaloid seborrheic dermatitis can predominately involve the face with psoriatic-appearing induration, plaques, and varying degrees of scales. "In skin of color, this can be confused with discoid lupus, sarcoidosis, and psoriasis, occasionally requiring a biopsy to distinguish," said Dr. Andrews, who is also an assistant professor of pediatrics at the Mayo Clinic College of Medicine and Science in Scottsdale, Ariz.

Another psoriasis mimicker, pityriasis amiantacea, is thought to be a more severe form of seborrheic dermatitis. It presents with concretions of scale around hair follicles that are highly adherent and are sometimes called sebopsoriasis. "It may be associated with cutaneous findings of psoriasis elsewhere, but may also be found with secondarily infected atopic dermatitis and tinea capitis; however, in my clinical experience, it is most often found in isolation," he said. "There may be a seasonal association with exacerbation in warm temperatures, and treatment often consists of humectants like salicylic acid for loosening scale, topical steroids for inflammation, and gentle combing out of scale."

Infections can also mimic psoriasis. For example, tinea infections are often misdiagnosed as eczema or psoriasis and treated with topical steroids. "This can lead to tinea incognito, making it harder to diagnose either condition without attention to detail," Dr. Andrews said. "On the body, look for expanding lesions with more raised peripheral edges, and central flattening, giving a classic annular appearance. It's also important to inquire about family history and contacts including pets, contact sports/mat sports (think yoga, gymnastics, martial arts), or other contacts with similar rashes." Work-up typically includes a fungal culture and starting empiric oral antifungal medications. "It is important to be able to distinguish scalp psoriasis from tinea capitis to prevent the more inflammatory form of tinea capitis, kerion (a deeper more symptomatic, painful and purulent dermatitis), which can lead to permanent scarring alopecia," he said.

Bacterial infections can also mimic psoriasis, specifically nonbullous impetigo and ecthyma, the more ulcerative form of impetigo. The most frequent associations are group AStreptococcus, methicillin-susceptibleStaphylococcus aureusand methicillin-resistantS. aureus.

Dr. Andrews closed his presentation by noting that tumor necrosis factoralpha inhibitorinduced psoriasiform drug eruptions can occur in psoriasis-naive patients or unmask a predilection for psoriasis in patients with Crohn's disease, juvenile idiopathic arthritis, or other autoinflammatory or autoimmune conditions. "They may improve with continued treatment and resolve with switching treatments," he said. "Early biopsy in psoriasiform drug eruptions can appear like atopic dermatitis on pathology. When suspecting psoriasis in a pediatric patient, it is important to consider the history and physical exam as well as family history and associated comorbidities. While a biopsy may aide in the work-up, diagnosis can be made clinically."

Dr. Andrews reported having no financial disclosures.

This article originally appeared onMDedge.com.

See the rest here:

Sorting Out the Many Mimickers of Psoriasis - Medscape

Scientific Solution for Sensitive Skin: Perricone MD Announces New Hypoallergenic CBD Sensitive Skin Therapy Collection – PRNewswire

SAN FRANCISCO, July 13, 2020 /PRNewswire/ -- Perricone MD continues its dedication to breakthrough, science-backed skincare solutions with a new collectionfeaturing 99% pure Cannabidiol (CBD), sourced in the United States, as the featured active ingredient. Drawing from loyal brand fan requests for a true sensitive skin care line, Perricone MD took innovation with CBD to the next level with the introduction of the Hypoallergenic CBD Sensitive Skin Therapy Collection.

Known for its soothing and calming benefits, CBD is a naturally-derived, powerful antioxidant that helps revitalize the look of stressed and problematic skin. Unlike other CBD products on the market, Perricone MD intentionally innovates with 99% Cannabidiol isolate to embrace the powerful ingredient in its most potent and pure form for maximum benefits. Other brands often use full- and broad-spectrum CBD, which contain impurities. With the combination of 99% pure Cannabidiol and other clean ingredients like Buriti Oil and Cherimoya Fruit Extract, this ultra-gentle regimen provides the ultimate relief for angry, irritated skin.

"We have led the category with CBD skincare innovation since 2017, first with our CBx for Men franchise, then with the addition of CBD to our Cold Plasma Plus+ Advanced Serum Concentrate in early 2020. As the ingredient has become more mainstream and widely accepted, we have decided to expand our portfolio through the introduction of Hypoallergenic CBD Sensitive Skin Therapy," says Robert Koerner, Perricone MD's Chief Marketing Officer. "We consistently hear from customers experiencing irritation that ultimately takes a toll on the skin's appearance, resulting in stressed and problematic texture. We are thrilled to be able to offer the collection as an effective solution for the angriest, stressed and irritated skin."

Recognized and approved by the National Psoriasis Foundation, the regimen is also suitable for individuals living with psoriasis and other severe sensitive skin conditions. "The National Psoriasis Foundation Seal of Recognition identifies products that have been created or are intended to be non-irritating and safe for people living with psoriasis and psoriatic arthritis," said Stacie Bell, Ph.D., chief scientific and medical officer, National Psoriasis Foundation. "With the addition of these products, we are excited to offer our psoriasis patient community an expanded number of quality products recognized to soothe symptoms specific to psoriasis."

Specifically developed for those with sensitive skin, the collection is non-comedogenic, dermatologist-tested and free of the 26 known allergens as well as fragrance, gluten, sulfates, silicones, parabens, formaldehyde, butylene- and propylene-glycol, PEG, phthalates, BHA and BHT.

The four-piece collection consists of the following:

Boasting impressive clinical results, the four-week study on the regimen showed improvement to skin barrier function, radiance, hydration, texture, tightness and elasticity. Additionally, the overall appearance of crepiness, fines lines and wrinkles was reduced**.

The Hypoallergenic CBD Sensitive Skin Therapy Collection is now available onSootheskin.PerriconeMD.com, available at Ulta Beauty, Ulta.com, Dillards.com, Macy's, Macys.com, EC Scott and ECScottgroup.com by early August.

*Based on a consumer study on 102 people over 28 days.**Based on a clinical study with 40 females over 28 days after using the full collection.

About Perricone MD

We Pick Up Where Nature Left Off.For over two decades, Perricone MD has been based around a three-tier, holistic skin and wellness system. It consists of an anti-inflammatory diet, essential dietary supplements and potent topical skincare solutions backed by some of the most powerful ingredients on the planet. Perricone MD was created by Dr.Nicholas Perricone, whoseNew York Timesbest-sellerThe Wrinkle Cureintroduced the world to the benefits of an anti-inflammatory lifestyle.Perricone MD is driven by the pursuit of fearless innovation and a stubbornly uncompromising spirit of excellence."We continuously seek the truth in unlocking the powerful science behind healthy-looking skin, from the inside out and outside in."

Perricone MD products feature some of the most potent ingredients on the planet that replenish the building blocks of healthy-looking skin, picking up where nature left off. The brand's award-winning patented sciences include: H2 Energy Complex, Nrf2 Antioxidant Support Complex, DMAE, Alpha Lipoic Acid, Vitamin C Ester, Acyl-Glutathione, and Neuropeptides. Perricone MD products are available onPerriconeMD.com, as well as UltaBeauty, Nordstrom, Dillard's, Lord & Taylor,Neiman Marcus, QVC and Sephora, and other leading specialty stores in the US. Perricone MD products are also available in more than 34 countries around the world in prestige retailers.

SOURCE Perricone MD

http://PerriconeMD.com

View original post here:

Scientific Solution for Sensitive Skin: Perricone MD Announces New Hypoallergenic CBD Sensitive Skin Therapy Collection - PRNewswire

SkinBioTherapeutics targets the promising skin microbiome market – Proactive Investors UK

The life sciences firm studies how to enhance and reintroduce the good bacteria on the skin

() has set out to make the skin feel and look better by studying the bacteria that live on its surface.

While most people know about the importance of having a healthy gut microbiome, the benefits of reinforcing good bacteria [probiotics] to the skin are yet to be discovered by the wider public.

But its a promising path: according to a Fortune Business Insights, the global probiotics market will reach US$74.7bn by the end of 2025 and the skin is going to be at the forefront of this growth.

The life sciences firm was spun out from () in 2015 and Opti remains the majority shareholder with a 29.8% stake.

SkinBioTherapeutics proprietary technology SkinBiotix is patented in various countries and based on studies conducted by Catherine ONeill and Andrew McBain at The University of Manchester.

The AIM-listed company is exploring five avenues of development: medical biotics; pharmabiotics; access biotics; cosmetics; and cleanbiotics.

Medical focuses on wound healing while pharma is analysed for prescribed treatment for skin conditions.

The two have a longer development path due to the regulatory hurdles to be crossed.

Access biotics, though, has recently passed major milestone through a partnership with Dutch firm Winclove Probiotics to develop a food supplement to alleviate symptoms of psoriasis.

The product, called AxisBiotix, may be ready for the shelves within a year.

The pair, which started collaborating in February, have already came up with the first formulation and are ready to enter a study on humans eight months ahead of schedule.

The whole access biotics project is to look at the pathways, what happens in the gut and how it manifests on the skin, so there are multiple places we could have started from, eczema, acne or psoriasis, chief executive Stuart Ashman told Proactive.

We chose psoriasis because its a particularly aggressive condition, it affects about 3% of the global population and there is no cure.

Many sufferers have had to enter complete coronavirus isolation because they take immunosuppressants to control the psoriasis outbreaks.

During a global pandemic the last thing in the world is suppress your immune system, you actually want that firing on all cylinders, so we firmly believe that its very, very important to get this into the community as quickly as possible, Ashman added.

Elsewhere,Ashmans team have been working with speciality chemical producer () since November to design and manufacture ingredients for the cosmetics market.

The initial target was enhancing the barrier effect of the skin to stop infections, but during the human safety studies the researchers came across significant anti-ageing indications, too.

The life sciences firm is providing its technology to the FTSE 100 companys unit Sederma, while SkinBioTherapeutics gets access to Sedermas huge base of customers, including prestigious brands such as Chanel, Garnier and LOreal.

Sederma has slowly restarted operations following a halt at the beginning of lockdowns, though there has been no material delay on their joint work.

Finally, infection control in both the home and the hospital environment has also taken on a new degree of urgency following the COVID-19 outbreak.

The skin is a very complicated surface, but it is just a surface, so we are doing the same thing on a non-living surfaces such as an operating table or bedsheets, explained Ashman.

In this application, the scientists are looking at how they can prevent the latching of bad bacteria onto surfaces.

Looking at the numbers, SkinBioTherapeutics is currently in the research and development phase, so its still pre-revenue.

First sales are estimated to come in around two years, which would be November 2021 for the deal with Croda and February 2022 for Winclove, although the timeline for the latter has now compressed significantly.

Cash at the end of June was around 2.1mln.

At current cash burn we do have a two-year window however, as we commence commercialisation and we start new rapid access trials, we will start burning cash a little faster, Ashman concluded.

Its going to be very busy. Regardless of what Covid-19 throws at us, we are looking to find all routes possible to get this psoriasis product into the hands of those that need it and progress on the other areas.

At 19.4p, the company is valued at 25mln.

More here:

SkinBioTherapeutics targets the promising skin microbiome market - Proactive Investors UK

DCGI approves limited use of psoriasis injection for Covid-19 – Hindustan Times

DCGI approves limited use of psoriasis injection for Covid-19 - india news - Hindustan Times "; forYoudata += ""; forYoudata += ""; forYoudata += ""; count++; if (i === 7) { return false; } }); forYouApiResponse=forYoudata; $(forutxt).html('Recommended for you'); $(foruContent).html(forYoudata); } } }); } else if(forYouApiResponse!=''){ $(forutxt).html('Recommended for you'); $(foruContent).html(forYouApiResponse); } } function getUserData(){ $.ajax({ url:"https://www.hindustantimes.com/newsletter/get-active-subscription?usertoken="+user_token, type:"GET", dataType:"json", success: function(res){ if(res.length>0) { $("[id^=loggedin]").each(function(){ $(this).hide(); }); } } }); } function postUserData(payLoad, elm){ var msgelm=$(elm).parents(".subscribe-update").nextAll("#thankumsg"); $.ajax({ url:"https://www.hindustantimes.com/newsletter/subscribe", type:"POST", data:payLoad, contentType: "application/json", dataType: "json", success: function(res){ if(res.success===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); } else if(res.exceptionResponse.alreadySubscribed===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); $(msgelm).find(".subscribed-successfully:first span.msg").text(res.exceptionResponse.message); } } }); }function captchverification(captchaResponse) {$('#captchaResponse').value = captchaResponse;$("#captcha-div").removeClass("block");$("body").removeAttr("style");var payLoad=JSON.stringify({ "domain": "HT", "emailId": email, "googleCaptcha": captchaResponse, "subscriptionTypes": [ "daily" ] });postUserData(payLoad,activeElm);} function subscribeNewsletter(inputText) { activeElm=inputText; var mailformat = /^w+([.-]?w+)*@w+([.-]?w+)*(.w{2,3})+$/; if(inputText.val().match(mailformat)) { inputText.focus(); email=inputText.val(); $("#captcha-div").addClass("block"); $("body").css("overflow","hidden"); return true; } else { alert("You have entered an invalid email address!"); inputText.focus(); return false; } } //DFP Ads var $dfpRightAd1 = $('.dfp-rightAd1-' + storyUuid); var $dfpRightAd2 = $('.dfp-rightAd2-' + storyUuid); var $dfpRightAd3 = $('.dfp-rightAd3-' + storyUuid); var $dfpRightAd4 = $('.dfp-rightAd4-' + storyUuid); var $dfpRightAd5 = $('.dfp-rightAd5-' + storyUuid); var $dfpStoryAd1 = $('.dfp-storyAd1-' + storyUuid); var $dfpStoryAd2 = $('.dfp-storyAd2-' + storyUuid); var $dfpStoryAd3 = $('.dfp-storyAd3-' + storyUuid); var $dfpStoryAd4 = $('.dfp-storyAd4-' + storyUuid); var $dfpStoryAd5 = $('.dfp-storyAd5-' + storyUuid); var $centerAd = $('.centerAd-' + storyUuid); getPersonlizeData(''); displayAd($dfpRightAd1,'/1055314/HT_StoryPages_300x250_Top',[[300, 250], [300, 600]]); displayAd($dfpRightAd2,'/3106570/HT_Desk_Story_BS_Multisize',['fluid', [300, 100]]); var rightMiddleScrollHandler = function () { if ($dfpRightAd3.isInViewport()) { displayAd($dfpRightAd3, '/1055314/HT_StoryPages_300x250_Middle', [[300, 250], [300, 600]]); $(window).off("scroll", rightMiddleScrollHandler); } } $(window).on("scroll", rightMiddleScrollHandler); var rightTabRepTopScrollHandler = function () { if ($dfpRightAd4.isInViewport()) { displayAd($dfpRightAd4, '/1055314/HT_Desk_Story_TabRep_Top_Multisize', [[300, 250], [300, 600]]); $(window).off("scroll", rightTabRepTopScrollHandler); } } $(window).on("scroll", rightTabRepTopScrollHandler); var rightTabRepBottomScrollHandler = function () { if ($dfpRightAd5.isInViewport()) { displayAd($dfpRightAd5, '/1055314/HT_Desk_Story_TabRep_Bottom_Multisize', [300, 250]); $(window).off("scroll", rightTabRepBottomScrollHandler); } } $(window).on("scroll", rightTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAd.isInViewport()) { displayAd($centerAd, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Inline story ads var storyAd1ScrollHandler = function () { if ($dfpStoryAd1.isInViewport()) { displayAd($dfpStoryAd1, storyAdList[0].ad, [728, 90]); $(window).off("scroll", storyAd1ScrollHandler); } } $(window).on("scroll", storyAd1ScrollHandler); var storyAd2ScrollHandler = function () { if ($dfpStoryAd2.isInViewport()) { displayAd($dfpStoryAd2, storyAdList[1].ad, [728, 90]); $(window).off("scroll", storyAd2ScrollHandler); } } $(window).on("scroll", storyAd2ScrollHandler); var storyAd3ScrollHandler = function () { if ($dfpStoryAd3.isInViewport()) { displayAd($dfpStoryAd3, storyAdList[2].ad, [728, 90]); $(window).off("scroll", storyAd3ScrollHandler); } } $(window).on("scroll", storyAd3ScrollHandler); var storyAd4ScrollHandler = function () { if ($dfpStoryAd4.isInViewport()) { displayAd($dfpStoryAd4, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyAd4ScrollHandler); } } $(window).on("scroll", storyAd4ScrollHandler); var storyAd5ScrollHandler = function () { if ($dfpStoryAd5.isInViewport()) { displayAd($dfpStoryAd5, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyAd5ScrollHandler); } } $(window).on("scroll", storyAd5ScrollHandler); validateUser($("#loggedin"),$("#loggedout")); if(user_token){ $("#loggedin .subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata,this); }); }else{ $("#loggedout .subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); } function ScrollMe(uuid) {var id = uuid.replace('story_','').trim(); id = id +"_story";var newid = uuid.trim();$('#ulInfinite').each(function() {var phrase = '';$(this).find('li').each(function(j, lix) {var myid = $(lix).attr('id');if (myid.trim() == newid.trim())$(lix).addClass("active");else$(lix).removeClass("active");});});var element = document.getElementById(id);element.scrollIntoView();element.scrollIntoView({behavior : "auto",block : "start",inline : "nearest"});$('html, body').animate({scrollTop : $("#" + newid).offset().top - 800}, 800, 'swing');}function InfiniteScroll() {var nextURL = listUrl[urlCount];var $container = $('.articles').infiniteScroll({path : function() {return nextURL;},append : '.article',status : '.scroller-status',hideNav : '.pagination',loadOnScroll : false,scrollThreshold : false});$container.infiniteScroll('loadNextPage');$container.on('history.infiniteScroll', function(event, title, path) {var currentID = "article_" + getStoryIdByUrl('https://www.hindustantimes.com/india-news/dcgi-approves-limited-use-of-psoriasis-injection-for-covid/story-bkVPzdJ7Y9oaCiX2NJkypO.html');var articleID = "article_" + getStoryIdByUrl(path);document.title = title;var temp = path.replace('.html', '').split('-');temp = temp.reverse();var forNid = temp[0].trim();$('#ulInfinite li').removeClass("active");$('#story_' + forNid).addClass("active");var n = gatag.includes(articleID, 0);if(n==false){gatag.push(articleID);showSkippablePopup();ga('send', {hitType : 'pageview',location : window.location.hostname.trim(),title : title.trim(),page : window.location.pathname.trim(),dimension15 : title});}window.snowplow("trackPageView", title);window.snowplow('resetPagePing');if (typeof COMSCORE != 'undefined'&& typeof COMSCORE.beacon !== 'undefined') {COMSCORE.beacon({c1 : "2",c2 : "6035286"});}});$container.on('load.infiniteScroll', function(event, response, path) {urlCount++;});var counter = 1;var uuid;$container.on('append.infiniteScroll', function(event, response, path, items) {uuid= $(items).find('.get-uuid').val();var elmLogin=$(items).find('#loggedin');var elmLogout=$(items).find('#loggedout');getPersonlizeData(items); validateUser(elmLogin,elmLogout); if(user_token){ getUserData(); $(elmLogin).find(".subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $(items).find("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata, this); }); }else{ $(elmLogout).find(".subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $(items).find("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); }var $dfpRightAd1ES = $(items).find('.dfp-rightAd1-'+uuid); var $dfpRightAd3ES = $(items).find('.dfp-rightAd3-'+uuid); var $dfpRightAd4ES = $(items).find('.dfp-rightAd4-'+uuid); var $dfpRightAd5ES = $(items).find('.dfp-rightAd5-'+uuid); var $centerAdES = $(items).find('.centerAd-' + uuid); var $dfpStoryAd1ES = $('.dfp-storyAd1-' + uuid);var $dfpStoryAd2ES = $('.dfp-storyAd2-' + uuid); var $dfpStoryAd3ES = $('.dfp-storyAd3-' + uuid); var $dfpStoryAd4ES = $('.dfp-storyAd4-' + uuid); var $dfpStoryAd5ES = $('.dfp-storyAd5-' + uuid); var isVideoExists = $(items).find('.video-js'); var isVideo=false; if (isVideoExists.length > 0) { isVideo=true; } var rightESTopScrollHandler = function () { if ($dfpRightAd1ES.isInViewport()) { displayAd($dfpRightAd1ES, rightAdList[0].ad, rightAdList[0].adsizes); $(window).off("scroll", rightESTopScrollHandler); } } $(window).on("scroll", rightESTopScrollHandler); var rightESMiddleScrollHandler = function () { if ($dfpRightAd3ES.isInViewport()) { displayAd($dfpRightAd3ES, rightAdList[1].ad, rightAdList[1].adsizes); $(window).off("scroll", rightESMiddleScrollHandler); } } $(window).on("scroll", rightESMiddleScrollHandler); var rightESTabRepTopScrollHandler = function () { if ($dfpRightAd4ES.isInViewport()) { displayAd($dfpRightAd4ES, rightAdList[2].ad, rightAdList[2].adsizes); $(window).off("scroll", rightESTabRepTopScrollHandler); } } $(window).on("scroll", rightESTabRepTopScrollHandler); var rightESTabRepBottomScrollHandler = function () { if ($dfpRightAd5ES.isInViewport()) { displayAd($dfpRightAd5ES, rightAdList[3].ad, rightAdList[3].adsizes); $(window).off("scroll", rightESTabRepBottomScrollHandler); } } $(window).on("scroll", rightESTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAdES.isInViewport()) { displayAd($centerAdES, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Story Inline ads var storyESAd1ScrollHandler = function () { if ($dfpStoryAd1ES.isInViewport()) { displayAd($dfpStoryAd1ES, storyAdList[0].ad2, [728, 90]); $(window).off("scroll", storyESAd1ScrollHandler); } } $(window).on("scroll", storyESAd1ScrollHandler); var storyESAd2ScrollHandler = function () { if ($dfpStoryAd2ES.isInViewport()) { displayAd($dfpStoryAd2ES, storyAdList[1].ad2, [728, 90]); $(window).off("scroll", storyESAd2ScrollHandler); } } $(window).on("scroll", storyESAd2ScrollHandler); var storyESAd3ScrollHandler = function () { if ($dfpStoryAd3ES.isInViewport()) { displayAd($dfpStoryAd3ES, storyAdList[2].ad2, [728, 90]); $(window).off("scroll", storyESAd3ScrollHandler); } } $(window).on("scroll", storyESAd3ScrollHandler); var storyESAd4ScrollHandler = function () { if ($dfpStoryAd4ES.isInViewport()) { displayAd($dfpStoryAd4ES, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyESAd4ScrollHandler); } } $(window).on("scroll", storyESAd4ScrollHandler); var storyESAd5ScrollHandler = function () { if ($dfpStoryAd5ES.isInViewport()) { displayAd($dfpStoryAd5ES, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyESAd5ScrollHandler); } } $(window).on("scroll", storyESAd5ScrollHandler); counter++;if (urlCount = n && o = n ? t.play() : t.pause()) : console.log("iOS") }) }); }}else if(isVideo){$(items).find("video[id^='myPlayerID_']").each(function(t, e) {var n = "myPlayerID_" + $(e).attr("data-video-id");bc(n), videojs(n).ready(function() {this.scrollIntoView()}) });}$(items).find("div[id^='right-swiper-']").each(function(i, e) {var swipID = $(e).attr("id");var storySwiper = new Swiper('#' + swipID, {pagination : {el : '.swiper-pagination',clickable : true},preloadImages : false,lazyLoading : true,simulateTouch : false,autoplay : {delay : 3000,}});});var ind = 0;$(items).find('.read-more').each(function(ind, obj) {ind = ind + 1;var html = $(items).find("#inlineStory" + ind).html();$(this).html(html);});$(items).find('img.lazy').each(function(i, e) {$(e).lazyload({effect : "fadeIn",effectTime : 20,threshold : 200,failurelimit : 0});});//getSeoContent(items);});}var reqOpen = true;$(document).bind("scroll",function() {var viewport = {top : $(document).scrollTop(),left : $(document).scrollLeft()};viewport.bottom = viewport.top + $(document).height();lastScrollTop = viewport.top;var bot = viewport.bottom - $(document).height();if (viewport.top > 200 && (showInfinite)) {if(isCorona && !loaded){var s= document.createElement('script');s.setAttribute('async','');s.src="https://chat.amplify.ai/plugin/5e77327dd8722a5cf17170be/chat_plugin.js?pluginId=5e77327dd8722a5cf17170be";document.getElementsByTagName('head')[0].appendChild(s);loaded=true;}$('.footer-scroll-main').show();if (reqOpen == true) {$('#ulInfinite li:first').addClass("active");$('#ulInfinite li .stroy-link').each(function(i, t) {if(i>0){listUrl.push($(t).html());}});InfiniteScroll();reqOpen = false;} } else if (bot

See more here:

DCGI approves limited use of psoriasis injection for Covid-19 - Hindustan Times